Vas Narasimhan, Novartis CEO (Gian Ehrenzeller/Keystone via AP)
August 18, 2023 06:52 AM EDT
R&D

No­var­tis lays out San­doz spin­off time­line with an Oct. 4 tar­get date af­ter share­hold­er vote

Katherine Lewin

News Reporter

No­var­tis is plan­ning on spin­ning off its gener­ic and biosim­i­lars arm San­doz around Oct. 4 of this year, and it will be

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

FDA re­jects Stealth's rare dis­ease drug, but of­fers po­ten­tial for ac­cel­er­at­ed ap­proval

Up­dat­ed: Trump ad­min­is­tra­tion halts more than $750M in funds for Mod­er­na’s bird flu vac­cine

Pep­Gen ditch­es Duchenne pro­grams af­ter mid-stage fail, switch­es to pre­vi­ous­ly halt­ed mus­cle wast­ing ther­a­py

Oric locks down cash for Phase 3 prostate can­cer tri­al with ear­ly da­ta in hand

Ex­clu­sive: Move­ment dis­or­der biotech Vi­ma steps on­to scene with $60M

sponsored

From weeks to days: how Aizon In­tel­li­gent Agents trans­form phar­ma val­i­da­tion

A service from the Financial Times